Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease
David Mengel1, Judith Dams1, Jannis Ziemek1
1Department of Neurology, Philipps-University, Marburg, Germany.
Parkinsonism & Related Disorders
|June 21, 2016
Summary
The apolipoprotein E (APOE) ε4 allele did not predict cognitive impairment in Parkinson's disease (PD) patients in this study. These findings suggest APOE ε4 is not a reliable biomarker for cognitive decline in PD.
Area of Science:
- Neuroscience
- Genetics
- Neurology
Background:
- Cognitive impairment is a frequent non-motor symptom in Parkinson's disease (PD).
- The apolipoprotein E (APOE) ε4 allele is a known risk factor for Alzheimer's disease and has been investigated for its potential role in PD-related cognitive decline.
Purpose of the Study:
- To investigate the association between the APOE ε4 allele and cognitive impairment in a cohort of Parkinson's disease patients.
- To determine if APOE ε4 predicts cognitive performance across various domains in PD.
Main Methods:
- Analysis of 447 Parkinson's disease patients from the German LANDSCAPE study.
- Comprehensive neuropsychological testing assessing memory, visuospatial function, attention, language, and executive function.
- APOE genotyping and linear regression to analyze associations with cognitive performance.
Main Results:
- The APOE ε4 allele was not significantly associated with a diagnosis of mild cognitive impairment or dementia in Parkinson's disease patients.
- No association was found between APOE ε4 and deficits in specific neuropsychological domains.
Conclusions:
- The APOE ε4 allele does not appear to be a relevant predictor of cognitive impairment in Parkinson's disease.
- These findings challenge the utility of APOE ε4 as a biomarker for cognitive decline in PD.
More Related Videos
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
8.4K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.4K
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:37Neural Regulation
44.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.1K
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
804
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
804